*In a 68-week clinical trial studying once-weekly semaglutide (2.4mg) in patients without diabetes and with BMI ≥30, or BMI ≥27 with a weight-related condition, the average weight loss was 15% when paired with lifestyle intervention (compared to 2.4% with lifestyle intervention alone).1

As an alternative to FDA-approved branded products, where appropriate, a provider may prescribe a compounded drug, which is prepared by a state-licensed sterile compounding pharmacy partner. Although compounded drugs are permitted to be prescribed under federal law, they are not FDA-approved and do not undergo safety, effectiveness, or manufacturing review.

Zepbound and Wegovy are FDA-approved for weight loss. Ozempic is FDA-approved for type 2 diabetes treatment, but may be prescribed off-label for weight loss at a healthcare provider’s discretion.